Source: International Congress 2019 – Modelling and monitoring of airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Naumov (Blagoveshchensk, Russian Federation), D. Gassan (Blagoveshchensk, Russian Federation), O. Kotova (Blagoveshchensk, Russian Federation), E. Sheludko (Blagoveshchensk, Russian Federation), E. Afanaseva (Blagoveshchensk, Russian Federation), J. Perelman (Blagoveshchensk, Russian Federation), Y. Shvetcova (Blagoveshchensk, Russian Federation). Role of interferon-gamma as a marker of asthma severity and control. 4378

Member's Comments

No comment yet.

Related content which might interest you: Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity Source: ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020 Year: 2021 Th-17 cytokine profile in a Greek asthmatic population. Correlation with asthma severity and biomarkers of inflammation. Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Role of neutrophils in maintenance of severity of non-allergic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 585s Year: 2007 The prognostic value of IFN-gamma and IL-4 cytokines ratio and CD25+ lymphocytes blood content for asthma exacerbation Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 The role of Hs-CRP in evaluating asthma severity and asthma control Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010 IL-33 mRNA in induced sputum cells from allergic rhinitis and asthma patients: a marker of Th-2 phenotype status? Source: International Congress 2017 – Monitoring asthma control Year: 2017 Exacerbation of experimental asthma depends on IL-6 but not on IL-23 or ROR?t Source: International Congress 2017 – Animal models of asthma and allergies Year: 2017 Expression of lymphocyte IL-4-receptor alpha chain in patients with severe asthma as a marker of severity of disease Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Use of interleukin-1beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1Ra) contents in alveolar macrophages for estimation of inflammation activity in patients with different levels of asthma control Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 Interleukin-4 and interleukin-5 are increased in asthma early in the course of the disease Source: Eur Respir J 2007; 30: Suppl. 51, 139s Year: 2007 The investigation of the role of interleukin (IL)-17 in COPD and asthma Source: Eur Respir J 2005; 26: Suppl. 49, 442s Year: 2005 Relationship between systemic IFNγ and IL5 levels and exacerbation frequency in COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 Serum levels of IL-8, IL-10 and TNFα in severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 279s Year: 2005 Induced sputum free interleukin-5 level and its mRNA expression in atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 548s Year: 2003 Lipoxin and eotaxin as markers of severity in patients with bronchial asthma Source: Annual Congress 2008 - Risk factors for allergic asthma and allergic rhinitis Year: 2008 Serum TNFα and IL8 as markers of systemic inflammation in severe asthma Source: Eur Respir J 2005; 26: Suppl. 49, 279s Year: 2005 Role of CD163 in human fatal asthma and murine asthma model. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Respiratory syncytial-virus induced cytokine production from leukocytes is impaired in severe asthma Source: Virtual Congress 2021 – New insight into the immunology of allergies, asthma and COPD: from mouse to man Year: 2021 Targeting the interleukin pathway in the treatment of asthma Source: International Congress 2015 – Asthma: emerging risk factors and current management of the patient Year: 2015 The role of IL-18 level and genetic polymorphism in patients with bronchial asthma and its relation to disease severity Source: Annual Congress 2012 - Gene-environment treatment and asthma Year: 2012